Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ: PSNL )

3.590 -0.230 (-6.02%)
Streaming Delayed Price Updated: 3:34 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
From Personalis, Inc.
Via Business Wire
Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce
Via Benzinga
Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
From Personalis, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Personalis's Return On Capital Employed Overview
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 152 stocks made new 52-week lows. 
Via Benzinga
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis Announces CEO Retirement and Transition
From Personalis, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
From Personalis, Inc.
Via Business Wire
Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Personalis, Inc.
Via Business Wire
Personalis Reports Third Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business
From Personalis, Inc.
Via Business Wire
Personalis to Announce Third Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
From Personalis, Inc.
Via Business Wire
121 Stocks That Hit Their 52-Week Low
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Personalis in Partnership with BC Cancer to Assess Clinical and Economic Benefits of ctDNA for Colorectal and Pancreatic Cancers
From Personalis, Inc.
Via Business Wire
5 Top Stocks Cathie Wood Bought This Week
Cathie Wood continues to increase positions in some of her top stocks despite recession fears. She bought names like EXAS and PACB this week. 
Via InvestorPlace
Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
From Personalis, Inc.
Via Business Wire
Personalis: Q2 Earnings Insights
Personalis (NASDAQ:PSNL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Personalis beat estimated... 
Via Benzinga
Personalis Reports Second Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
From Personalis, Inc.
Via Business Wire
Personalis to Announce Second Quarter 2022 Financial Results
From Personalis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.